Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | FPR2 | P25090 | 3/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453327 | 0.90 | PKM (0.69) | PKMFPR2ALDH1A1RAB9ANPC1 | |
| SCHEMBL19612835 | 0.90 | PKM (0.54) | PKMFPR2ALDH1A1RAB9ANPC1 | |
| SCHEMBL20862403 | 0.86 | TAS1R3 (0.57) | PKMFPR2TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL702263 | 0.79 | TAS1R3 (0.60) | PKMFPR2TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL12068702 | 0.79 | TAS1R3 (0.56) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL12407169 | 0.79 | RAB9A (0.73) | PKMFPR2ALDH1A1RAB9ANPC1 | |
| SCHEMBL18844837 | 0.77 | ENPP2 (0.55) | PKMTAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL7413029 | 0.76 | FPR2 (0.58) | FPR2ALDH1A1RAB9ANPC1POLB | |
| SCHEMBL23406285 | 0.76 | PKM (0.67) | PKMFPR2ALDH1A1RAB9APOLB | |
| SCHEMBL26749387 | 0.75 | RAB9A (0.63) | PKMFPR2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | PKM 1722/4885FPR2 1138/4885TAS1R3 4806/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | PKM 1722/4885FPR2 1138/4885TAS1R3 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.